On March 18, 2010, Roche is holding its investor conference in New York. This investor conference is the first following the successful integration of Roche and Genentech, and the company is highlighting the vision and strategy it intends to pursue in order to ensure a stable flow of novel medicines from its rich development pipeline.
Join the conference call or webcast, beginning at 9:00 a.m. Eastern Standard Time or join the replay of the conference call or webcast.
Genentech Research and Early Development (gRED) is a key contributor to Roche's diversity of approaches to innovation. During the investor conference, Dr. Richard Scheller, Global Head of gRED, is presenting an overview of the organization's efforts to translate science into innovative new therapies to improve and extend lives.
Download Dr. Scheller's presentation (2.83MB/PDF) to learn more about gRED's growing pipeline and recent scientific discoveries or hear Dr. Scheller's remarks.